Group One Trading
ALDX icon

Group One Trading’s Aldeyra Therapeutics ALDX Stock Holding History

Group One Trading’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$197K Sell
116,700
-63,700
-35% -$279K ﹤0.01% 4122
2025
Q4 		$934K Sell
180,400
-5,500
-3% -$28.3K ﹤0.01% 2955
2025
Q3 		$970K Buy
185,900
+153,500
+474% +$800K ﹤0.01% 3064
2025
Q2 		$124K Sell
32,400
-262,300
-89% -$678K ﹤0.01% 4780
2025
Q1 		$1.69M Buy
294,700
+190,200
+182% +$1.12M ﹤0.01% 1968
2024
Q4 		$521K Buy
104,500
+28,400
+37% +$146K ﹤0.01% 3141
2024
Q3 		$410K Buy
76,100
+4,000
+6% +$19K ﹤0.01% 3013
2024
Q2 		$239K Buy
72,100
+16,500
+30% +$64.6K ﹤0.01% 3250
2024
Q1 		$182K Buy
55,600
+15,200
+38% +$50K ﹤0.01% 3639
2023
Q4 		$142K Buy
40,400
+28,100
+228% +$86.7K ﹤0.01% 4173
2023
Q3 		$82.2K Sell
12,300
-14,500
-54% -$108K ﹤0.01% 4636
2023
Q2 		$225K Buy
26,800
+12,500
+87% +$123K ﹤0.01% 3810
2023
Q1 		$142K Buy
14,300
+300
+2% +$2.12K ﹤0.01% 3986
2022
Q4 		$97.4K Sell
14,000
-44,100
-76% -$252K ﹤0.01% 4467
2022
Q3 		$310K Sell
58,100
-117,300
-67% -$704K ﹤0.01% 3697
2022
Q2 		$700K Buy
175,400
+148,000
+540% +$509K ﹤0.01% 3109
2022
Q1 		$122K Sell
27,400
-124,600
-82% -$496K ﹤0.01% 5300
2021
Q4 		$608K Sell
152,000
-31,100
-17% -$237K ﹤0.01% 3902
2021
Q3 		$1.61M Buy
183,100
+81,800
+81% +$751K ﹤0.01% 2883
2021
Q2 		$1.15M Buy
101,300
+76,200
+304% +$916K ﹤0.01% 3248
2021
Q1 		$298K Buy
25,100
+21,700
+638% +$250K ﹤0.01% 4582
2020
Q4 		$23K Sell
3,400
-4,700
-58% -$33K ﹤0.01% 5432
2020
Q3 		$60K Sell
8,100
-31,900
-80% -$206K ﹤0.01% 4528
2020
Q2 		$167K Buy
+40,000
New +$146K ﹤0.01% 3535
2019
Q4 		– Sell
-1,100
Closed -$6K – 5064
2019
Q3 		$6K Sell
1,100
-1,300
-54% -$7K ﹤0.01% 4710
2019
Q2 		$14K Sell
2,400
-16,200
-87% -$122K ﹤0.01% 4298
2019
Q1 		$168K Buy
18,600
+15,500
+500% +$132K ﹤0.01% 2824
2018
Q4 		$26K Sell
3,100
-9,700
-76% -$99.4K ﹤0.01% 3896
2018
Q3 		$177K Buy
12,800
+7,500
+142% +$60.8K ﹤0.01% 3097
2018
Q2 		$42K Sell
5,300
-2,400
-31% -$19.1K ﹤0.01% 4039
2018
Q1 		$58K Buy
+7,700
New +$58.5K ﹤0.01% 3578

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Group One Trading's ALDX Position: Q1 2026 in Review

Group One Trading sold out of Aldeyra Therapeutics (ALDX) in Q1 2026, closing a stake of 83,449 shares — an estimated $366K sold.

Group One Trading first reported a position in ALDX in Q2 2018 and held it in 27 quarters. The position peaked at $1.02M in Q4 2024. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Group One Trading reported no remaining Aldeyra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 83,449 Aldeyra Therapeutics shares in Q1 2026, an estimated $366K.
  • Group One Trading first reported a position in Aldeyra Therapeutics in Q2 2018 and held it in 27 quarters.
  • Group One Trading's Aldeyra Therapeutics position peaked at $1.02M in Q4 2024.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.